Radioprotectives | Centrum biomedicínského výzkumu

Telephone switchboard
+420 495 831 111

cze
  • Hospital
    • COVID19 information
    • University Hospital Hradec Králové
    • Departments
    • Management
    • History
    • Numbers
    • Faculty of Medicine in Hradec Králové
  • Emergency
    • Emergency Service
    • Emergency Service for Adults
    • Emergency Service for Children
    • Emergency Dental Care
    • Emergency Pharmacy
  • Research
    • Research and Science
    • Centre for Transfer of Biomedical Technologies
    • Biomedical Research Center
  • Photos
    • Present
    • History
    • Projects
  • Contact
    • Address
    • Map
    • Bank Accounts

Radioprotectives

  For Czech version click here

The team is focused on the design, synthesis, in vitro screening and in vivo testing of PUMA inhibitors as radioprotective agents in the anti-cancer therapy and for irradiated personnel exposed within radiation accidents or radiation terrorism.

Radiotherapy is one of the most important modalities in oncolgy. Its therapeutic potential is, however, limited by toxicity issues associated with irradiation of normal tissues. Both acute and chronic radiotoxicity have been associated with cell death. In radiosensitive tissues such as bone marrow or gastrointestinal tract, the cell death is predominantly mediated with programmed cell death - apoptosis. A pro-apoptotic protein PUMA plays a key role in this process. Thus, Inhibition of its functions increases resistance against radiation. Small molecule inhibitors of PUMA seem therefore very promising in respect to selective modulation of normal tissue damage. Such may also find its use as radioprotectors in radiation accidents or radiation terrorism.

Working group performs:

  • in silico design of novel drugs
  • design and synthesis of small molecule inhibitors targeting protein PUMA (p53 upregulated modulator of apoptosis)
  • evaluation of radioprotective effect on model cell lines, determination of cytotoxicity
  • evaluation of radioprotective effect of successful candidates from in vitro trials on animal models (mouse, rat, porcine) in vivo

Team:

assoc. prof. PharmDr. Ales Tichy, PhD.

Miroslav Psotka, PhD.

PharmDr. Jan Marek, PhD.

 

 


  • Jobs
  • Introduction
  • Our team
  • Laboratories
  • Working groups
    • Novel anti-Alzheimer´s therapeutics
    • Desinfection and decontamination compounds
    • Anticancer drugs
    • Antituberculosis drugs
    • Antidotes
    • Proteomics
    • Radioprotectives
  • Cooperation
  • Contact
  • Our projects
  • List of publications
Ministerstvo zdravotnictví České Republiky Akreditace, program kvality
Prohlášení o přístupnosti © Copyright 2021 FN HK. All rights reserved. | webmaster